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Disease
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 First identified as a cause of diarrhea in 1973 
 Leading cause of severe gastroenteritis among U.S. children 
before introduction of vaccine in 2006 
Nearly universal infection by age 5 years
Responsible for up to 500,000 diarrheal deaths each year 
worldwide 
Rotavirus 
 Two important outer shell proteins—VP7, 
or G-protein, and VP4, or P-protein define 
the serotype of the virus 
 From 1996–2005, five predominate strains 
in the U.S. (G1–G4, G9) accounted for 90% 
of the isolates
 G1 strain accounts for 75% of infections 
 Very stable and may remain viable for 
weeks or months if not disinfected 
Rotavirus 
Antibody against VP7 and VP4 probably important for 
protection 
• Cell-mediated immunity probably plays a role in recovery and 
immunity
 First infection usually does not lead to permanent immunity
Reinfection can occur at any age
Subsequent infections generally less severe 
Rotavirus Immunity 
Short incubation period 
 First infection after 3 months of age generally most severe 
May be asymptomatic or result in severe, dehydrating 
diarrhea with fever and vomiting 
Gastrointestinal symptoms generally resolve in 3–7 days
Rotavirus Clinical Features
 Infection can lead to severe diarrhea, dehydration, electrolyte 
imbalance, and metabolic acidosis
 Immunocompromised children may experience severe 
prolonged gastroenteritis
May have abnormalities in multiple organ systems, especially 
the kidney and liver
Rotavirus Complications
World-wide distribution
• Similar in developed and developing countries
Reservoir
• Human–GI tract and stool 
Transmission
• Fecal–oral, fomites
Temporal pattern
• Fall and winter (temperate areas)
Communicability
• 2 days before to 10 days after onset of symptoms
Rotavirus Epidemiology 
Annually responsible for:
• 3 million infections
• More than 400,000 physician visits
• 200,000 emergency dept. visits
• 55,000–70,000 hospitalizations
• 20–60 deaths
$1 billion in direct and indirect costs
Rotavirus Disease in the United States
Prevaccine Era
Infect Dis. 2010 Jun 1;201(11):1617-24. 
Impact of Rotavirus Vaccine Introduction
https://www.cdc.gov/mmwr/volumes/68/wr/mm6824a2.htm?s_cid=mm6824a2_w#F1_down
Rotavirus: What You Should Know 
Children’s Hospital of Philadelphia Vaccine Education Center http://media.chop.edu/data/files/pdfs/vaccine-education-center-rotavirus.pdf
Rotavirus
Vaccine
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Rotavirus Vaccines 
Vaccine product Age indications
Single-component vaccines
RotaTeq (RV5) 6 weeks to 32 weeks of age 
Rotarix (RV1) 6 weeks to 24 weeks of age 
Any rotavirus gastroenteritis 
• 74–87% 
Severe gastroenteritis 
• 85–98%
Both vaccines have significantly reduced physician visits for 
diarrhea and reduced rotavirus-related hospitalizations 
No ACIP preference for one product (RV5 vs. RV1) over the 
other
Rotavirus Vaccine Efficacy 
Rotavirus 
Clinical 
Considerations
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 2 RV1 or 3 RV5 oral doses beginning at 2 months of age
• May be started as early as 6 weeks of age 
 For both rotavirus vaccines:
• Maximum age for first dose is 14 weeks, 6 days*
• Minimum interval between doses is 4 weeks 
• Maximum age for any dose is 8 months, 0 days 
Rotavirus Vaccination Schedule 
*ACIP off-label recommendation for both vaccines because the labeled maximum age for the first dose of RV5 is 12 weeks 
ACIP did not define a maximum interval between doses 
Doses of rotavirus vaccine should be separated by at least       
4 weeks
No rotavirus vaccine should be administered to infants older 
than 8 months, 0 days*
 It is not necessary to restart the series or add doses because 
of a prolonged interval between doses 
Rotavirus Vaccination Schedule
*ACIP off-label recommendation for both vaccine products because the labeled maximum age for RV1 is 24 weeks, and the labeled maximum age for RV5 is 32 weeks
ACIP recommends that providers do not repeat the dose if the 
infant spits out or regurgitates the vaccine 
Any remaining doses should be administered on schedule 
• Doses of rotavirus vaccine should be separated by at least 4 weeks
Complete the series with the same vaccine product whenever 
possible 
Rotavirus Vaccine Recommendations 
 If product used for a prior dose or doses is not available or not 
known, continue or complete the series with the product that is 
available 
 If any dose in the series was RV5 (RotaTeq) or the vaccine brand 
used for any prior dose is not known, a total of 3 doses of 
rotavirus vaccine should be administered 
 Infants documented to have had rotavirus gastroenteritis before 
receiving the full course of rotavirus vaccinations should still begin 
or complete the 2- or 3-dose schedule 
Rotavirus Vaccine Recommendations 
Preparation: 
• RV5: None
• RV1: Must be reconstituted BEFORE administering
Route/Site: Administer ORALLY (PO)
• The infant may eat or drink immediately following vaccine 
administration
May be administered during the same clinical visit as other 
vaccines 
Rotavirus Vaccine Administration 
 Route: 
• RV1 inadvertently injected 
o The dose does NOT count. Re-administer the vaccine ORALLY ASAP
 Schedule errors: 
• 1st dose was inadvertently given after 14 weeks, 6 days (maximum age)
o The dose counts
o Administer the remaining doses of the series at the routinely recommended intervals
o Timing of the first dose should not affect the safety and efficacy of the remaining doses
• Any dose after 8 months, 0 days (maximum age) 
o Rotavirus vaccine should not be given after age 8 months, 0 days even if the series is 
incomplete
Vaccine Administration Errors 
Severe allergic reaction to a vaccine component (including 
latex) or following a prior dose of vaccine 
• RV1 (Rotarix) oral applicator contains latex rubber
History of intussusception
Severe combined immunodeficiency (SCID) 
Rotavirus Vaccine Contraindications
Altered immunocompetence (except SCID, which is a 
contraindication) 
• Limited data do not indicate a different safety profile in HIV-infected 
versus HIV-uninfected infants 
• HIV diagnosis not established in infants due for rotavirus vaccine 
• Vaccine strains of rotavirus are attenuated 
• These considerations support rotavirus vaccination of HIV-exposed or 
infected infants 
Rotavirus Vaccine Precautions*
*The decision to vaccinate if a precaution is present should be made on a case-by-case risk and benefit basis.
Acute, moderate, or severe gastroenteritis or other acute 
illness 
The decision to vaccinate if a precaution is present should be 
made on a case-by-case risk and benefit basis
Rotavirus Vaccine Precautions 
 Intussusception 
• RV1 postlicensure evaluation–1 to 3 excess cases per 100,000 first 
doses, possible risk for RV5 cases too small to confirm 
• Vaccine Adverse Event Reporting System (VAERS) reports show event 
clusters in 3–6 days following RV5 
• Vaccine Safety Datalink (VSD) shows no increased risk of 
intussusception (unable to assess RV1)  
Rotavirus Vaccine Adverse Events 
RV5 (RotaTeq) 
• Diarrhea 18.1%
• Vomiting 11.6%
• Also greater rates of otitis media, nasopharyngitis, and bronchospasm 
RV1 (Rotarix)
• Irritability 11.4% 
• Cough or runny nose 3.6% 
• Flatulence 2.2%
Rotavirus Vaccine Adverse Reactions 
 Store rotavirus vaccines in a refrigerator 
between 2°C–8°C (36°F–46°F) 
 Store in the original packaging with the 
lids closed in a clearly labeled bin and/or 
area of the storage unit 
• Protect the vaccine from light 
 Store RV1 (Rotarix) diluent in the 
refrigerator with the vaccine or at room 
temperature up to 25°C (77°F)
 Do not freeze vaccine or diluent
Vaccine Storage and Handling 
Rotavirus
Resources
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Ask the Experts–Rotavirus FAQs: 
www.immunize.org/askexperts/experts_rota.asp
CDC Rotavirus Disease and Vaccination: 
www.cdc.gov/rotavirus/index.html
Questions and Answers–Rotavirus What You Should Know: 
https://media.chop.edu/data/files/pdfs/vaccine-education-
center-rotavirus.pdf
 Standing Orders for Administering Rotavirus Vaccine: 
www.immunize.org/catg.d/p3087.pdf
Rotavirus Vaccine Standing Orders 
Immunization Action Coalition website accessed 4/8/2018 
Hepatitis 
A
Disease
1
Epidemic jaundice described by Hippocrates
Differentiated from hepatitis B in 1940s
Serologic tests developed in 1970s
Vaccines licensed in 1995 and 1996
Until 2004, hepatitis A was the most frequently reported type 
of hepatitis in the U.S.
Hepatitis A
 Incubation period 28 days (range 15–50 days)
 Illness not specific for hepatitis A
 Likelihood of symptomatic illness directly related to age
Children generally asymptomatic, adults symptomatic
Hepatitis A Clinical Features
Reservoir Human
Transmission Fecal–oral
Temporal pattern None
Communicability 2 weeks before to 1 week after onset of jaundice
Hepatitis A Epidemiology
 Hepatitis A outbreaks in 
10 states have occurred 
primarily among persons 
who:
• Use injection and 
noninjection drugs 
• Are homeless
• Are their close, direct 
contacts
Hepatitis A Outbreak 2017-2019 
https://www.cdc.gov/hepatitis/outbreaks/2017March-HepatitisA.htm
Hepatitis
A
Vaccine
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Hepatitis A-Containing Vaccines
Vaccine product Age indications
Havrix
Pediatric formulation Birth – 18 years
Adult formulation 19 years and older
Vaqta
Pediatric formulation Birth – 18 years
Adult formulation 19 years and older
Twinrix
Adult formulation 18 years and older
Administer the appropriate formulation based on the patient’s age 
Twinrix (HepA-HepB) combination vaccine contains:  
• Hepatitis A 720 EL.U. (pediatric dose) 
• Hepatitis B 20 mcg (adult dose) 
Approved for persons 18 years of age and older
Schedules
• 3-dose: 0, 1, 6 months 
or
• 4-dose: 0, 7, 21–30 days and booster dose at 12 months after first dose
Hepatitis A-Containing Vaccines 
 Large outbreaks of Hepatitis A among adults in several US cities resulted in 
increased demand for vaccine and constrained vaccine supply
 In response, CDC has
• Collaborated with manufacturers to understand options for managing supplies in the 
public and private sector and increasing national supply
• Increased vaccine availability on CDC’s adult vaccine contracts 
 Available vaccine supplies have increased and progress has been made 
regarding ongoing outbreaks
 Manufacturers have supply to meet current demand
 CDC and vaccine manufacturers are monitoring the demand and need for adult 
Hepatitis A vaccine 
 Note, supply constraints do not apply to the pediatric Hepatitis A vaccine supply 
Vaccine Supply
CDC website: Current Vaccine Shortages and Delays. Accessed 7/23/2019 https://www.cdc.gov/vaccines/hcp/clinical-resources/shortages.html#note1
 HAVRIX (GSK)
• 40,000 Thai children 1 to 16 years of age 
• Vaccine efficacy 94%
 VAQTA (Merck)
• 1,000 New York children 2 to 16 years of age 
• Vaccine efficacy 100%
 Twinrix (GSK)
• 1,551 healthy adults 17 to 70 years of age
• Vaccine efficacy HepA 99.9% and HepB 98.5%
Hepatitis A Vaccine Efficacy 
Hepatitis A
Clinical 
Considerations
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 All children should receive vaccine at 12 through 23 months of age 
 Vaccination should be integrated into the routine vaccination schedule 
 Catch-up all unvaccinated children between 2 and 18 years*
 Vaccination of all children 12 months and older with HIV infection*
ACIP Hepatitis A Vaccine Recommendations: Pediatric 
*Newly voted on recommendations by ACIP. New recommendations will be published soon in MMWR once approved by CDC director
Existing hepatitis A vaccination programs for children 2–18 
years of age should be maintained
New efforts for routine vaccination of children 12 months of 
age should enhance, not replace, ongoing vaccination 
programs for older children
Areas without an existing hepatitis A vaccination program can 
consider catch-up vaccination for unvaccinated children 2-18 
years of age 
Hepatitis A Vaccination of Children 
ACIP Hepatitis A Vaccine Recommendations: Adult 
 Administer vaccine to adults at increased risk, including:
• Travel to or work in areas with high or intermediate endemicity
• Close, personal contact with an international adoptee from an area with high 
or intermediate endemicity
• Men who have sex with men
• Injection or noninjection drug use
• Clotting factor disorders
• Work with nonhuman primates or in a hepatitis A research laboratory 
setting
• Chronic liver disease
• Adults who report homelessness
• Healthy adults who have recently been exposed to hepatitis A
• Persons living with HIV*
ACIP HepA Vaccine Recommendations: Adult 
* Newly voted on recommendations by ACIP. New recommendations will be published soon in MMWR once approved by CDC director
Hepatitis A and International Travel 
World Health Organization map of countries of area of risk for hepatitis A. Accessed 4/3/2018. 
http://gamapserver.who.int/mapLibrary/Files/Maps/Global_HepA_ITHRiskMap.png?ua=1. 
 Administer a single dose of HepA
vaccine to infants 6–11 months of 
age*
 Infants should restart the 2-dose 
series of HepA vaccine at 12 
months of age or older as 
recommended
Hepatitis A Vaccine for International Travelers:
Infants  
https://www.cdc.gov/mmwr/volumes/67/wr/mm6743a5.htm
One dose of a monovalent hepatitis A vaccine protects most 
healthy people 1–40 years of age
Administer HepA vaccine to persons 1 year of age and older 
• Start the series as soon as travel is being considered to an area outside 
the U.S. where protection against hepatitis A is recommended 
• The series should be completed for lifelong protection – even if the trip 
is over
• Postvaccination testing is not recommended
Hepatitis A Vaccination for International Travelers: 
Children and Adults 
MMWR 2007;56(No.41):1080-4
Summary: Hepatitis A Vaccine Recommendations and 
International Travel 
1https://www.cdc.gov/mmwr/volumes/67/wr/mm6743a5.htm
2 If measles is not endemic in the region 
3Based on provider guidance risk assessment and availability of vaccine or IG
Age
Infants less than 6 months of age Immunoglobulin (IG)
Infants 6 through 11 months of age Vaccine1 (or IG2)
Healthy persons 1 year of age or older Vaccine
Special Populations 
Persons with a vaccine contraindication IG
Immunocompromised persons Vaccine with addition of IG3
Persons with chronic liver disease Vaccine
Pregnant women Vaccine
Adult formulation hepatitis A vaccine may be used to 
complete a schedule begun with Twinrix and vice versa*
Acceptable schedules
• 2 Twinrix and 1 hepatitis A (adult formulation)
• 1 Twinrix and 2 hepatitis A (adult formulation)
Maintain spacing recommended for Twinrix 
Twinrix and Single-Component Hepatitis A Vaccine
*Use the pediatric formulation of single-component vaccine for persons 18 years of age and younger.
Use the adult formulation of single-component vaccine for persons 19 years of age or older.
Hepatitis A vaccination for unvaccinated persons who 
anticipate close, personal contact during the first 60 days after 
arrival of an international adoptee from a country of high or 
intermediate endemicity
Administer dose 1 as soon as adoption is planned, ideally 2 or 
more weeks before the arrival of the adoptee
Vaccination for Close Contacts of 
Newly Arriving International Adoptees
MMWR 2009;58(No.36):1006-7
Not routinely recommended for:
• Health care personnel
• Child care center staff
• Sewer workers or plumbers
 Food handlers may be considered based on local 
circumstances
Hepatitis A Vaccination Additional Recommendations
Prevaccination serologic testing is not indicated for children
• Older adolescents: Testing may be cost-effective for certain populations
Postvaccination
• Not indicated
Hepatitis A Serologic Testing
Route: IM injection 
• Needle gauge: 22 – 25 gauge
• Needle length*: 1 – 1.5 inch depending on the patient’s age and/or 
weight 
Site*: 
• 1-3 years:  Vastus lateralis muscle is preferred; deltoid muscle may be 
used if the muscle mass is adequate 
• 4 years and older: Deltoid muscle is preferred; vastus lateralis muscle 
may be used
Hepatitis A Vaccine Administration 
*Professional judgement should be used to determine the proper needle length and site.  Influencing factors include injection technique, local reaction, number of vaccines to 
be administered, patient age, size and muscle mass
Hepatitis A 
Vaccine Administration Errors 
*If meets minimum age and interval (if applicable) 
We administered: Now:
Adult formulation to a 
child 
Dose counts, revaccination is not indicated*
HepB, Hib, or HPV 
instead of HepA vaccine 
Dose does not count toward completion of the 
HepA series 
Severe allergic reaction to a vaccine component or following a 
prior dose
Moderate or severe acute illness
Hepatitis A Vaccine
Contraindications and Precautions
 Local reaction 20% - 50%
Systemic reactions
(malaise, fatigue) Less than 10%
No serious adverse reactions reported
Hepatitis A Vaccine 
Adverse Reactions
 Store hepatitis A vaccine in a 
refrigerator between 2°C-8°C 
(36°F-46°F) 
 Store pediatric and adult 
formulations:
• In the original packaging with the 
lids closed
• In a clearly labeled bin and/or 
area of the storage unit-not next 
to each other 
Vaccine Storage and Handling 
Vaccine storage label example
Available at www.cdc.gov/vaccines/hcp/admin/storage/guide/vaccine-storage-labels.pdf
Vaccines administered outside the U.S. can be accepted as 
valid if the schedule is similar to U.S. recommendations
With the exception of influenza and PPSV23 vaccines, only 
written documentation should be accepted as evidence of 
previous vaccination
General Recommendations for 
Persons Vaccinated Outside the U.S.
ACIP General Best Practice Guidelines on Immunizations https://www.cdc.gov/mmwr/pdf/rr/rr6002.pdf
Questions? Health care providers may:
• Repeat the vaccinations–safe and prevents the need for serologic 
testing
• Use serologic testing judiciously-may avoid unnecessary injections
o But for most vaccines, many serologic tests cannot document protection against 
infection
o Cost can be a factor
Determining What to Do Next 
ACIP General Best Practice Guidelines on Immunizations https://www.cdc.gov/mmwr/pdf/rr/rr6002.pdf
Hepatitis 
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Ask the Experts–Hepatitis A FAQs: 
www.immunize.org/askexperts/experts_hepa.asp
CDC Hepatitis A Disease: www.cdc.gov/hepatitis/hav/index.htm
CDC Hepatitis A Vaccination: 
www.cdc.gov/vaccines/vpd/hepa/hcp/index.html
 Standing Orders for Administering Hepatitis A Vaccine: Children 
and Teens: www.immunize.org/catg.d/p3077a.pdf
Child Resources
2018 Binational 
Immunization 
Resource Tool for 
Children from Birth 
through 18 Years 
Foreign Language Terms Job Aids 
CDC. 2017 Binational Immunization Resource Tool for Children from Birth through 18 Years https://www.cdc.gov/vaccines/schedules/downloads/child/binational-schedule-pr.pdf
CDC. Epidemiology and Prevention of Vaccine-Preventable Diseases, 13th edition, Appendix B  https://www.cdc.gov/vaccines/pubs/pinkbook/index.html
IAC: Quick Chart of Vaccine-Preventable Disease Terms in Multiple Languages http://www.immunize.org/catg.d/p5122.pdf
Appendix B: Foreign 
Language Terms: Aids 
to translating foreign 
immunization records
Quick Chart of 
Vaccine-Preventable 
Disease Terms in 
Multiple Languages 
Immunization Action Coalition website accessed 4/8/2018 children http://www.immunize.org/catg.d/p3077a.pdf adult http://www.immunize.org/catg.d/p3077.pd
Ask the Experts–Hepatitis A FAQs: 
www.immunize.org/askexperts/experts_hepa.asp
CDC Hepatitis A Disease: www.cdc.gov/hepatitis/hav/index.htm
CDC Hepatitis A Vaccination: 
www.cdc.gov/vaccines/vpd/hepa/hcp/index.html
 Standing Orders for Administering Hepatitis A Vaccine: Adults: 
www.immunize.org/catg.d/p3077.pdf
Adult Resources
A Quick Look at Twinrix Job Aid
Michigan Department of Health and Human Services http://www.michigan.gov/documents/mdch/QuickLookUsingTwinrix091708_250029_7.pdf
Hepatitis A Vaccine Standing Orders for
Children and Adults
Immunization Action Coalition website accessed 4/8/2018 children http://www.immunize.org/catg.d/p3077a.pdf adult http://www.immunize.org/catg.d/p3077.pd
